Journal: Cell
Article Title: Posttranslational modifications mediate the structural diversity of tauopathy strains
doi: 10.1016/j.cell.2020.01.027
Figure Lengend Snippet: (A-D) Representative neuropathological changes in the frontal cortex of a patient with CBD. Ballooned neurons revealed by H&E staining (A, arrow) and immunolabeling with CP13 (B, arrow). CP13 immunostaining also labels neuritic threads (B-D), as well as pleomorphic small neuronal inclusions (C, arrows) and astrocytic plaques (D, asterisk). Scale bar equal to 20 microns (A-D). (E) Sarkosyl-insoluble material from the frontal cortex of the CBD patient used for cryo-EM analysis was evaluated by Western blot, including the tau antibodies PHF1 (pS396/404), Tau46 (aa404–441) and 12E8 (pS262, pS356). (F) Representative immuno-electron microscopy images of sarkosyl-insoluble tau filaments purified from CBD brain and stained with tau phospho-specific antibodies PHF1 and 12E8, as well as ubiquitin (Ubi-1). Primary antibodies were visualized with secondary antibody conjugated with 6 nm gold particles. Scale bar equal to 30 nm. (G) Representative cryo-EM images of the singlet and doublet tau fibrils in CBD. Scale bar equal to 100 Å. (H) Pronase treatment eliminates ubiquitin immunoreactivity from sarkosyl-insoluble core. To examine the impact of pronase treatment on ubiquitination of the filament core in tauopathies, the sarkosyl insoluble fraction was obtained and incubated in the presence or absence of pronase (1, 2, or 5 minute treatment), and subsequently evaluated by dot blot (including anti-ubiquitin and the tau antibodies E1 [aa19–33], CP13 [pS202], 12E8, PHF1, and Tau46). (I) Schematic diagram depicting the location of the antibody epitope within the tau protein. Note the amount of each sarkosyl-insoluble fraction was normalized for total tau levels. See also Figures S1 and S5.
Article Snippet: An average of 10 z-slices from the (A) CBD doublet fibril and (C) AD straight filament (EMD-3743) cryo-EM 3D reconstructions reveals strong, large densities visibly attached to K 321 and K 353 on the CBD doublet map and K 317 , K 321 , and K 311 on the AD straight filament (red dashed circles).
Techniques: Staining, Immunolabeling, Immunostaining, Cryo-EM Sample Prep, Western Blot, Immuno-Electron Microscopy, Purification, Incubation, Dot Blot